Back to News
Market Impact: 0.35
AbbVie Completes Acquisition of Apogee Therapeutics
Source: PR Newswire
M&A & RestructuringHealthcare & BiotechCompany FundamentalsCorporate Guidance & Outlook
AbbVie’s acquisition (via Apogee) deepens its immunology pipeline by adding diverse late-stage assets targeting dermatologic, respiratory, and other inflammatory diseases. The lead candidate, zumilokibart, is a half-life extended monoclonal antibody targeting IL-13 and is described as late-stage in development, supporting continued expansion of AbbVie’s immunology growth platform.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
ABBV0.35
APOG0.30
More News
- ADARx Pharmaceuticals Seeks IPO On Strong Collaboration Deal With AbbVie
- Jim Cramer's top 10 things to watch in the stock market Thursday
- Apple makes biggest change to iPhone release cadence in 7 years in Ternus' first showcase as CEO
- What Wall Street thought of Apple's foldable iPhone and what the Duo means for the stock
- Amazon backs Ariane with rocket launch orders as Europe battles to close its space gap
- Trump’s ‘Big Beautiful Bill’ projected to add a big, unbeautiful $3.4 trillion to the national debt over the next decade